Tioguanin is named as an intervention in 8 current clinical trials in our Australia, Canada, Mexico, Israel, Germany, Italy, Switzerland, Austria, Czechia, France, Netherlands, Belgium and Sweden registers. 3 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (4). The most-studied condition is B Acute Lymphoblastic Leukemia.
From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
| Study | Phase | Status | Lead sponsor | Registers |
|---|
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Tioguanin on the HPRA medicines list.
No entry for Tioguanin in the EMA, FDA or German BfArM shortage lists we track.
| Condition (as registered) | Trials |
|---|---|
| B Acute Lymphoblastic Leukemia | 4 |
| Mixed Phenotype Acute Leukemia | 2 |
| B Lymphoblastic Lymphoma | 2 |
| Down Syndrome | 2 |
| Acute Lymphoblastic Leukemia | 1 |
| T Acute Lymphoblastic Leukemia | 1 |
| Acute Lymphoblastic Leukemia, Pediatric | 1 |
| Central Nervous System Leukemia | 1 |
| Recurrent B Acute Lymphoblastic Leukemia | 1 |
| Acute Myeloid Leukemia | 1 |
| Myelodysplastic Syndrome | 1 |
| Myeloid Leukemia Associated With Down Syndrome | 1 |
| Adult T Acute Lymphoblastic Leukemia | 1 |
| Ann Arbor Stage II Adult Lymphoblastic Lymphoma | 1 |
| Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | 1 |
| Ann Arbor Stage III Adult Lymphoblastic Lymphoma | 1 |
| Lead sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 4 |
| Children's Oncology Group | 3 |
| Martin Schrappe | 1 |
A trial with sites in more than one country appears in each of those registers.
8 current trials in our Australia, Canada, Mexico, Israel, Germany, Italy, Switzerland, Austria, Czechia, France, Netherlands, Belgium and Sweden registers name Tioguanin as a drug or biological intervention, as of the registry sync on 2 October 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 8 trials are recruiting: 3 with sites in Australia, 2 with sites in Canada, 2 with sites in Mexico, 2 with sites in Israel, 1 with sites in Germany, 1 with sites in Italy, 1 with sites in Switzerland, 1 with sites in Austria and 1 with sites in Czechia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
National Cancer Institute (NCI) (4), Children's Oncology Group (3) and Martin Schrappe (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Tioguanin, for example Lanvis 40mg Tablets (Aspen Pharma Trading Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Tioguanin has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tioguanin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tioguanin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tioguanin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 2 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
